Drug Approval | July 03, 2022
Pfizer submits new drug application to the U.S. FDA for Paxlovid
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
The compendium was released by Suman Bery, Vice-Chairman, NITI Aayog and Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and WCD.
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Subscribe To Our Newsletter & Stay Updated
